Considering the daily timeframe, the stock has given a downward sloping trendline breakout formed by connecting swing highs since August 11, 2020. This breakout is confirmed by the above 50-day average volume.

The consolidated net sales reported in Q1FY21 came in at Rs 778.51 crore, which increased by 17.81 per cent YoY from Rs 660.81 crore in Q1FY20.

Earlier this month, the company had announced a plan to invest Rs 1 lakh crore, which would help the company to achieve 1 billion tonnes (BT) coal production by the year 2023-24.

On Friday, the domestic benchmark indices saw volatility during the week’s last trading session. Sensex and Nifty closed flat with a positive bias. Sensex edged up by a mere 0.04 per cent or 14.23 points to settle at 38,854.55 while Nifty gained by 0.13 per cent or 15.20 points to close at 11,464.45.

Risk is simply the probability of losing money on an investment. A more technical definition of risk would be the volatility of return on the investment. An asset with erratic returns is considered to be riskier than an asset, whose value stays rather static or moves slowly.

Zydus Cadila has received final approval from USFDA to market Doxorubicin Hydrochloride Liposome injection in the strengths of 20 mg/10 ml (2 mg/ml) and 50 mg/25 ml (2 mg/ml) single-dose vials.

The consolidated net sales reported in Q1FY21 came in at Rs 2,910.83 crore, which increased by 2.29 per cent YoY from Rs 2,845.64 crore in Q1FY20. 

Penny stocks have made a come back in 2020. Several penny stocks have become multibaggers and are catching investors attention.

Also on the production front, the company has beaten the production target of its main revenue component Urea. It has produced 16.11 lakh MT of Urea during April-August 2020 as against 14.26 lakh MT produced during the same period in 2019-20.

Over a period of 5 years the stock has generated 109.4 per cent returns on an annualised basis while over three years the stock has delivered 97.60 per cent on an annualised basis.